病情分析:乳腺癌的IDFS和DFS是两个不同的概念。IDFS是指无疾病生存期(invasivedisease-freesurvival),而DFS是指疾病无进展生存期(disease-freesurvival)。 具体来说,IDFS包括对初始乳腺癌的治疗成功后,在接下来的时间内没有出现新的浸润性乳腺癌或其他类型的肿瘤。这个时间通常被定义为手术后5年或10年。因此,IDFS是...
乳腺癌的DFS和IDFS的区别,主要在于是否有浸润性癌的出现。两者统计差别的数字,即原位癌出现复发转移的数字。两者密切相关而又不等同,DFS是指disease疾病、Free没有疾病、survival生存,即没有疾病的生存,翻译为无病生存。IDFS中的I是指invasive,即浸润性疾病,整体而言就是无浸润性癌生存。DFS指的是既没有浸润性疾病...
1.Gabriel N. Hortobagyi, et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis...
Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial...
Hortobagyi GN, Lacko A, Sohn J, et al. A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial. Ann Oncol. 2024 Oct 21:S0923-7534(24)04...
Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2− early breast cancer: final invasive disease–free survival (iDFS) analysis from the NATALEE trial 瑞波西利(RIB)+非甾体类芳香化酶抑制剂(NSAI)辅助治疗HR+/HER2−早期乳腺癌患者:NATALEE...
neoadjuvant trastuzumab and taxane-based chemotherapy. The primary endpoint of the study is invasive disease-free survival (iDFS), defined as the time from randomization to invasive breast cancer recurrence or death from any cause. Secondary endpoints are disease-free survival and overall survival (OS...
这篇研究利用真实世界患者数据,评估 HR+/HER2–早期乳腺癌(EBC)中无侵袭性疾病生存期(iDFS)作为总生存期(OS)替代终点的可行性。结果显示二者存在强正相关,支持 iDFS 用于相关临床试验,为治疗评估提供新视角。 研究背景 在HR+/HER2–早期乳腺癌(EBC)的治疗中,总生存期(OS)是评估治疗效果的 “金标准”,但它需要...
(pCR)–adapted treatment regimen comprising trastuzumab (Herceptin) in combination with pertuzumab (Perjeta) with or without endocrine therapy was safe and generated a high 3-year invasive disease-free survival (iDFS) rate in patients with HER2-positive early breast cancer, meeting a coprimary en...
Adjuvant ribociclib plus standard non-steroidal aromatase inhibitors improved invasive disease-free survival in HR-positive, HER2-negative early breast cancer, compared with nonsteroidal aromatase inhibitors alone. Breast Cancer Image: © Giovanni Cancemi- stock.adobe.com ...